January 2024 in “Wiadomości Lekarskie” DEC cells show promise as a safe and effective treatment for Duchenne muscular dystrophy.
71 citations
,
May 2024 in “New England Journal of Medicine” Ruxolitinib may effectively treat APS-1 by reducing harmful immune responses.
1 citations
,
January 2024 in “Pharmaceuticals” A new carrier improves skin delivery of tofacitinib for treating inflammatory skin diseases.
28 citations
,
December 2017 in “Journal of Investigative Dermatology Symposium Proceedings” Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.
January 2004 in “Indian Journal of Nephrology” January 2018 in “Journal of Investigative Dermatology” Blocking certain pathways with kinase inhibitors may help treat cutaneous lupus erythematosus.
May 2025 in “JEADV Clinical Practice” Tofacitinib and methotrexate successfully treated a woman's severe skin, joint, and hair loss issues.
YH0618 helps reduce chemotherapy-induced hair loss by targeting specific proteins and pathways.
August 2016 in “PolyPublie (École Polytechnique de Montréal)” Doxorubicin causes heart damage, so early detection and monitoring are important during chemotherapy.
53 citations
,
July 2018 in “Drug design, development and therapy” Janus kinase inhibitors show promise in treating alopecia areata but need better topical formulations.
November 2025 in “Clinical and Translational Allergy” The consensus provides guidelines for safely stopping danazol in hereditary angioedema treatment.
Tofacitinib significantly improved symptoms in a patient with overlapping autoimmune disorders.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib provides new treatment options for diverse alopecia areata patients.
12 citations
,
May 2015 in “Journal of the National Comprehensive Cancer Network” Doctors should actively prevent and treat skin side effects in cancer patients to keep them on the best medication and reduce discomfort.
143 citations
,
May 2002 in “PubMed” LGD1069 effectively prevents breast tumors in mice without toxicity.
February 2025 in “International Journal of STD & AIDS” Tofacitinib can cause unusual hair growth, requiring careful monitoring and possible laser hair removal.
26 citations
,
October 2018 in “Clinical & Translational Oncology” Spanish experts provided guidelines for treating skin side effects in cancer patients on new therapies, stressing early action and teamwork.
1 citations
,
January 2023 in “Portuguese Journal of Dermatology and Venereology” JAK inhibitors effectively treat skin conditions and topical forms are safer.
Low-dose sorafenib can cause severe facial acne, treatable with topical medication.
October 2025 in “Pharmaceuticals” Auranofin shows promise as a cancer treatment, especially when combined with other therapies.
June 2011 in “Oncology times” Dr. Mario Lacouture recommends preventive and specific treatments for skin side effects caused by EGFR inhibitors to improve patients' quality of life.
15 citations
,
July 2010 in “Journal of Allergy and Clinical Immunology” A new cream, DHMEQ, reduces allergic skin inflammation effectively.
May 2010 in “OPAL (Open@LaTrobe) (La Trobe University)” Vaccines and targeting TrxR variants can help prevent cancer and reduce metastasis.
July 2024 in “Journal of Investigative Dermatology” PH-762 shows promise in treating skin cancer by effectively targeting and silencing PD-1 in tumors with minimal side effects.
8 citations
,
May 2020 in “Arthritis research & therapy” DHT inhibition may increase spinal bone growth in ankylosing spondylitis.
January 2024 in “Journal of dermatology and skin science” Topical aprepitant reduces skin rash and hair loss caused by cancer treatment.
November 2025 in “Eurasian journal of applied biotechnology” Combining L-cysteine, NAC, and a MET inhibitor significantly kills cervical cancer cells.
March 2023 in “JAAD case reports”
May 2024 in “Journal of molecular structure” A new compound, 3a, effectively fights prostate cancer better than finasteride.
21 citations
,
June 2017 in “Case Reports in Dermatology” Reducing gefitinib dosage improved hair loss, but scarring remained.